Byrn lab:Research: Difference between revisions
DeEtte Starr (talk | contribs) mNo edit summary |
DeEtte Starr (talk | contribs) mNo edit summary |
||
| Line 2: | Line 2: | ||
<div style="padding: 10px; width: 720px; border: 5px solid #CC9933;"> | <div style="padding: 10px; width: 720px; border: 5px solid #CC9933;"> | ||
<p><em>Solid state chemistry of drugs and formulation design. Study of polymorphs, nanoparticles, liquid crystals, cocrystals, and amorphous materials. Analytical methods in the solid state including X-ray diffraction and solid state NMR. Molecular basis of manufacturing. Sustainable medicine in Africa.</em></p> | <p><strong>Major Research Interests:</strong><em>Solid state chemistry of drugs and formulation design. Study of polymorphs, nanoparticles, liquid crystals, cocrystals, and amorphous materials. Analytical methods in the solid state including X-ray diffraction and solid state NMR. Molecular basis of manufacturing. Sustainable medicine in Africa.</em></p> | ||
Revision as of 10:13, 2 January 2013
Major Research Interests:Solid state chemistry of drugs and formulation design. Study of polymorphs, nanoparticles, liquid crystals, cocrystals, and amorphous materials. Analytical methods in the solid state including X-ray diffraction and solid state NMR. Molecular basis of manufacturing. Sustainable medicine in Africa.
The solid state chemistry of drugs is being studied to:
- improve knowledge of the factors that affect this chemistry;
- develop new analytical methods;
- develop platforms for formulation design especially as they relate to new formulations that reduce dose;
- understand the molecular basis of manufacturing, and
- be able to assess the risk of instability of APIs and formulations.
Of special interest is the use of synchrotron technologies to:
- analyze amorphous materials and liquid crystals; and
- use levitated drops and synchrotron radiation to develop platforms to accelerate drug development.
This solid state research has implications for formulation design, the analysis of drugs, the stability of drugs, the control of drug manufacturing, and the development of methods of crystallization. By carrying out research on the solid state chemistry of drugs it is hoped that new approaches for drug analysis including X-ray PDF methods and solid state NMR methods will be developed. Finally, all of this information is used to develop new formulations that provide equivalent bioavailability of marketed drugs at reduced dose. Research is also ongoing to develop new formulations and manufacturing technologies to increase access to medicines in Africa.
Current Research Projects
1. Formulation design for reduced dose formulations
2. Formulation design strategies to accelerate drugs to proof of concept and for translational research
3. Nanoparticle preparation and analysis
4. Synchrotron methods to screen for amorphous formulations
5. Preparation, crystallization, and scale-up of cocrystals
6. Molecular basis of manufacturing
Dr. Byrn also founded ImprovedPharma and SSCI, Inc.
<html><DIV align=right> Hosted by <a href="http://www.openwetware.org"><img src="http://openwetware.org/images/0/01/80x15_openwetware.png" border=0/></a></DIV></html>
